Bioinvent
Bioinvent: No drama in Q1 - key milestones approaching (Redeye)

2019-05-22 17:18
Today’s Q1 2019 earnings report was mostly uneventful. All the 2019 catalyst remain on track, and the closest is a first look of the data from the ongoing combination study with BI-1206, expected in mid-June. Following the report, we reiterate our base case fair value of SEK 4.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

BioInvent International - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -